Rege Nephro Co., Ltd.
PrivateLast Round
Convertible Debt
Jun 22, 2026
Total Funding Raised
$13.01M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Rege Nephro Co., Ltd. is a biotechnology company that develops therapeutics and cell therapy for kidney, liver, and pancreas diseases using induced pluripotent stem cell (iPSC) technology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Rege Nephro Co., Ltd. Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Rege Nephro Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Jun 22, 2026 | ||||
| Series B | Oct 7, 2024 | ||||
| Debt | Nov 1, 2023 | ||||
| Series A | Jan 31, 2022 | ||||
| VC Round | Jun 4, 2020 |
Key People
Founding team and executive leadership
Rege Nephro Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Chushin Venture Capital | Convertible Debt, Series B, Series A |
| JAFCO Group Co., Ltd. | Convertible Debt, Series B, Series A |
| Sparx Asset Management | Convertible Debt |
| 株式会社日本政策金融公庫 | Debt |
| Tohoku University Venture Partners | Series B |
| DCI Partners | Convertible Debt, Series B |
| 日本ベンチャーキャピタル株式会社 | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors increased 57% MoM, reaching 2.6K.
- Feb 26, 2025
Acquired tamibarotene-related assets from Syros Pharmaceuticals.
Rege Nephro Co., Ltd. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Rege Nephro Co., Ltd.'s valuation, stock price, and market status.